Celltrion biopharmaceuticals
Scope
Date
~
-
Bio & Pharma
Celltrion applies for Phase 3 clinical trials in Europe for biosimilar
South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...
May 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey
South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...
Apr 21, 2023 (Gmt+09:00)
-
Bio & Pharma
GeneOne Life Science gets patent for coated microneedle tech in China
South Korea’s biopharmaceutical company GeneOne Life Science Inc. on Tuesday said it received a patent from the China National Intellectual Pr...
Apr 19, 2023 (Gmt+09:00)
-
Private equity
MBK Partners co-founder tops 50 richest S.Koreans: Forbes
Michael ByungJu Kim, co-founder and partner at private equity firm MBK Partners, has topped the ranking of the 50 richest South Koreans by net worth...
Apr 18, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Celltrion Healthcare launches Vegzelma in US
South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorecta...
Apr 17, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals wins Red Dot award for 2 devices
South Korea’s SK Biopharmaceuticals on Tuesday said two of its self-developed wearable devices won the main prize in the health care category ...
Apr 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Biosimilar giant Celltrion to transform into drug developer
South Korean biosimilar giant Celltrion Group aims to transform into a drug developer by generating 40% of sales from new medicines by 2030 as it is...
Mar 29, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion founder returns to management with M&A pledge
South Korean biosimilar giant Celltrion Group’s founder Seo Jung-jin has returned to management two years after his departure, pledging to mer...
Mar 28, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion eyes Baxter's arm as it gears up for M&As
Celltrion Inc., South Korea’s largest biosimilar maker, said on Tuesday it has studied a possible acquisition of the biopharma solutions unit ...
Mar 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Genuv sign agreement for antibody joint R&D
South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday a joint research and development agreement with Genuv, Inc., a domestic drug...
Mar 14, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion ex-Chairman Seo set to return to management; group stocks rally
South Korea’s biosimilar giant Celltrion Group’s founder and Honorary Chairman Seo Jung-jin is readying to return to management just two...
Mar 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion teams up with bio venture to develop new anti-cancer drug
South Korea's biopharmaceutical company Celltrion Inc. will develop an anti-cancer drug that combines oncolytic virus technology with biosimilars un...
Feb 28, 2023 (Gmt+09:00)
-
Bio & Pharma
Dubai delegation conducts due diligence on Medytox's plant in Korea
South Korea's biopharmaceutical firm Medytox Inc. said on Monday that a high-level delegation led by Dubai Science Park (DSP) under Dubai's state-ow...
Feb 28, 2023 (Gmt+09:00)
-
Bio & Pharma
Brazil approves Celltrion Pharm’s syringe facility
Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...
Feb 20, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Truxima shows safety, efficacy in post-marketing study
South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...
Feb 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan
Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...
Jan 26, 2023 (Gmt+09:00)
-
Chief Executives
Samsung Biologics CEO focuses on global business
John Rim, chief executive of Samsung BioLogics will directly lead his company's global sales operations for biopharmaceuticals through contract deve...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion increases its stake in British ADC developer Iksuda
Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wed...
Jan 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year
South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to tre...
Jan 11, 2023 (Gmt+09:00)
-
Bio & Pharma
SK bio families to present visions to global investors at SK Bio Night
SK Inc., the investment company of SK Group, said on Tuesday that it will hold a networking event called "SK Bio Night" in the US along with its bio...
Jan 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
Jan 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Kolon signs MOU with Hanyang Univ. to develop gene therapy treatments
Kolon Industries Inc.'s Future Technology Institute said on Thursday that it had signed a memorandum of understanding with the Hanyang University In...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion acquires approval to sell Vegzelma in Canada
South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
S.Korean biopharmaceutical sector to see brisk M&As in H1, 2023
An expert says the first half of next year will see the start of brisk M&As in biopharmaceuticals targeting strategic investors.Pyeon Jae-seong,...
Dec 21, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals launches epilepsy drug in France
South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company l...
Dec 09, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion to seek FDA approval for sale of Remsima SC by year-end
Celltrion Inc. said it has confirmed the effectiveness and safety of Remsima SC in its third-phase global clinical trials, conducted on 438 patients...
Nov 28, 2022 (Gmt+09:00)